Leadership Team

Dr. Gary Kay is the developer and publisher of CogScreen. From 1985 to 1998, Dr. Kay served as the Director of the Neuropsychology Division of the Georgetown University School of Medicine’s Department of Neurology. In this capacity he was actively engaged in
teaching, clinical service, and research. His research activities focused on development of computerized methods for assessing higher cortical functions, and investigation of the neuropsychological sequelae of HIV infection, head injury, fibromyalgia, diabetes, eosinophilia myalgia syndrome, alcoholism, and normal aging. Dr. Kay has served as the Principal Investigator on single and multi-center clinical drug trials investigating the effects of medications on cognition, mood, and sychomotor performance. Recent studies have investigated changes in cognition associated with sedating antihistamines, hormone replacement therapy, and nutritional supplements. In 1998 Dr. Kay established the Washington Neuropsychological Institute, a firm that conducted contract research and educational programs for federal agencies (e.g., Federal Aviation Administration, Social Security Administration) and industry.

Dr. Kay is an Associate Professor of Neurology at Georgetown University. He received his Ph.D. in psychology (Clinical Neuropsychology Specialty Program) at the University of Memphis (formerly Memphis State University). He completed his psychology internship at the National Naval Medical Center, Bethesda, Maryland.
Dr. Kay is a Fellow of the National Academy of Neuropsychologists and a member of the International Neuropsychological Society and the American Psychological Association. He is a diplomat of the American Board of Assessment Psychology.

Dr. Kay has been an invited speaker at professional meetings across the United States and around the world. He has presented to the Institute of Medicine of the National Academy of Sciences, testified to U.S. Congressional committees, provided testimony at FDA hearings, and serves as a consultant to numerous governmental, corporate, and medical organizations. He has written several book chapters and authored numerous peer-reviewed articles that have appeared in Archives of Internal Medicine, American Psychologist, Human Psychopharmacology, British Journal of
Pharmacology, Aviation Space and Environmental Medicine, Annals of Allergy,and the American Journal of Managed Care.

Dr. Hochadel has over 18 years of experience in the planning, management, and conduct of clinical research trials. Prior to joining Cognitive Research Corporation, Dr. Hochadel was the President of Advanced Research Corporation where he was responsible for the overall management and financial health of a full-service Contract Research Organization. Previous to that he was Senior Director, Psychiatry and Neurology, with SCIREX Corporation and Director of Clinical Operations CNS Center with Covance Inc, where he actively managed senior Project Managers, cross-functional project teams, and all clinical aspects of CNS studies. Dr. Hochadel also has six years of experience as Director of Clinical Research at Somerset Pharmaceuticals, Inc., where he was responsible for the generation of preclinical-to-post-marketing development plans and regulatory submissions. Dr. Hochadel was Somerset’s responsible party for two Investigational New Drug Applications and conducted more than 30 Phase I clinical studies.

Dr. Hochadel’s Phase I clinical trial experience has included multiple dose studies in healthy elderly subjects, tyramine challenge pressor tests, and extensive evaluations of transdermal systems including pharmacokinetic and wearability assessments. His expertise in Phase II-IV development is highlighted by his work in dementia, including a 48-week chronic dosing study in Alzheimers disease subjects and Nursing Home based studies targeting behavioral signs and symptoms of dementia. He also has experience with depression, mania, attention deficit/hyperactivity disorder, Tourettes syndrome, schizophrenia, Parkinson’s disease, and sleep disorder trials. Dr. Hochadel was also the responsible party for an anti-osteoporosis compound IND and development program.

Dr. Hochadel received his Pharm.D. from Mercer University Southern School of Pharmacy in Atlanta, Georgia and his BS in natural sciences from the University of South Florida in Tampa, Florida. Dr. Hochadel is a Registered Pharmacist and is frequently involved with international medical missions.

Mr. Horohonich has over 20 years of experience in the pharmaceutical and contract research organization business. Prior to joining Cognitive Research Corporation, Mr. Horohonich was the Vice President of Advanced Research Corporation where he was responsible for the overall data management and statistical functions of a full-service Contract Research Organization. Previous to this, he was Associate Director of Data Management at Covance where he managed the Nashville based data management department. Mr. Horohonich also has six years of experience as Therapeutic Group Leader at Pfizer Inc., where he was responsible for the management of all data management activities for a global CNS program in Schizophrenia. Mr. Horohonich also spent four years at Bristol Myers Squibb where he was responsible for all data management activities on a global hypertension program. Prior to joining Bristol Myers Squibb, Mr. Horohonich spent four years as a scientist in the department of cardiovascular pharmacology at Smith Kline and French Labs.

Mr. Horohonich’s Phase II-III clinical trial experience includes the successful submission of four New Drug Applications. His expertise in Phase II-III development is highlighted by his work in Schizophrenia and hypertension. He also has experience with depression, migraine, agitation, arthritis, asthma, osteoporosis, congestive heart failure, diabetes, and oncology.

Mr. Horohonich received his Bachelor of Science from Cook College, Rutgers University in New Jersey. Mr. Horohonich is a member of the Drug Information Association faculty and teaches a course in Data Management.

Dr. Azzaro is a Neuropharmacologist with more than 35 years of research experience in basic neuropharmacology, clinical pharmacology and pharmacokinetics, and drug development in neurological and psychiatric disorders. His professional background includes academic teaching and research at West Virginia University School of Medicine where he held the rank of Professor in the Departments of Neurology, Psychiatry, and Pharmacology/Toxicology. He also served as Director of Scientific Operations at the Covance CNS Center (Covance, Inc.) and as Chief Scientific Officer with Somerset Pharmaceuticals, Inc. where he played a major role in the NDA preparation and the 2006 FDA approval of EMSAM® for the treatment of Major Depressive Disorder.
Dr. Azzaro has authored more than 150 manuscripts and scientific abstracts, and 5 book chapters. In addition to his work at Cognitive Research Corporation, Dr. Azzaro maintains an Adjunct Appointment as Professor in the Department of Molecular Pharmacology and Physiology at the University of South Florida College of Medicine, Tampa, Florida.
At Cognitive Research Corporation, Dr. Azzaro specializes in the design and direction of studies in preclinical pharmacology, human pharmacokinetics, CNS imaging, and pharmacodynamics related to drug mechanism of action and/or safety. He is skilled at manuscript preparation for scientific publication, and he directs Phase II/III clinical trials in neurological and psychiatric disorders.

Director, Clinical Projects

Eva M. Kemper, MSHS, CRC’s Director of Clinical Projects, has over 16 years of clinical trial and regulatory experience. Prior to joining CRC in 2007, Ms. Kemper was Manager, Clinical Trials at Somerset Pharmaceuticals, Inc. In that role, she managed Phase I – III clinical research projects for depression, Parkinson’s Disease, ADHD and Alzheimer’s Disease. Ms. Kemper was also an integral part of a team that submitted several hundred IND submissions and three NDA’s. Prior to working in the pharmaceutical industry, Ms. Kemper worked at FDA as a spokesperson for the Center for Drug Evaluation and Research in the Public Affairs Office.